206 related articles for article (PubMed ID: 18042588)
1. Role of distinct immune components in the radiation-induced abrogation of systemic lupus erythematosus development in mice.
e Brito RR; De Lorenzo BH; Xander P; Godoy LC; Lopes JD; da Silva NP; Sampaio SC; Mariano M
Lupus; 2007; 16(12):947-54. PubMed ID: 18042588
[TBL] [Abstract][Full Text] [Related]
2. IL-4Ralpha polymorphism in regulation of IL-4 synthesis by T cells: implication in susceptibility to a subset of murine lupus.
Shiroiwa W; Tsukamoto K; Ohtsuji M; Lin Q; Ida A; Kodera S; Ohtsuji N; Nakamura K; Tsurui H; Kinoshita K; Nishimura H; Shirai T; Hirose S
Int Immunol; 2007 Feb; 19(2):175-83. PubMed ID: 17189592
[TBL] [Abstract][Full Text] [Related]
3. Treatment of lupus-prone NZB/NZW F1 mice with recombinant soluble Fc gamma receptor II (CD32).
Werwitzke S; Trick D; Sondermann P; Kamino K; Schlegelberger B; Kniesch K; Tiede A; Jacob U; Schmidt RE; Witte T
Ann Rheum Dis; 2008 Feb; 67(2):154-61. PubMed ID: 17557887
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of lupus disease by anti-double-stranded DNA antibodies of the IgM isotype in the (NZB x NZW)F1 mouse.
Werwitzke S; Trick D; Kamino K; Matthias T; Kniesch K; Schlegelberger B; Schmidt RE; Witte T
Arthritis Rheum; 2005 Nov; 52(11):3629-38. PubMed ID: 16255055
[TBL] [Abstract][Full Text] [Related]
5. An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.
Bahjat FR; Pine PR; Reitsma A; Cassafer G; Baluom M; Grillo S; Chang B; Zhao FF; Payan DG; Grossbard EB; Daikh DI
Arthritis Rheum; 2008 May; 58(5):1433-44. PubMed ID: 18438845
[TBL] [Abstract][Full Text] [Related]
6. Transgene-mediated hyper-expression of IL-5 inhibits autoimmune disease but increases the risk of B cell chronic lymphocytic leukemia in a model of murine lupus.
Wen X; Zhang D; Kikuchi Y; Jiang Y; Nakamura K; Xiu Y; Tsurui H; Takahashi K; Abe M; Ohtsuji M; Nishimura H; Takatsu K; Shirai T; Hirose S
Eur J Immunol; 2004 Oct; 34(10):2740-9. PubMed ID: 15368290
[TBL] [Abstract][Full Text] [Related]
7. Subset size, activation threshold and distribution of autoreactive MZ and FO B cells do not differ in a sex-specific manner in the NZB/W F1 murine lupus model: an experimental mouse study.
Enghard P; Grussie E; Rieder C; Burmester GR; Riemekasten G
Lupus; 2011 Oct; 20(12):1240-9. PubMed ID: 21844114
[TBL] [Abstract][Full Text] [Related]
8. Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.
Borel P; Benkhoucha M; Weber MS; Zamvil SS; Santiago-Raber ML; Lalive PH
Int Immunol; 2008 Oct; 20(10):1313-9. PubMed ID: 18687587
[TBL] [Abstract][Full Text] [Related]
9. Ongoing immunologic activity after short courses of pulse cyclophosphamide in the NZB/W murine model of systemic lupus erythematosus.
Austin HA; Patel AD; Cadena CA; Boumpas DT; Balow JE
J Rheumatol; 1997 Jan; 24(1):61-8. PubMed ID: 9002012
[TBL] [Abstract][Full Text] [Related]
10. Accelerated deaths from systemic lupus erythematosus in NZB x NZW F1 mice treated with the testosterone-blocking drug flutamide.
Walker SE; Besch-Williford CL; Keisler DH
J Lab Clin Med; 1994 Sep; 124(3):401-7. PubMed ID: 8083583
[TBL] [Abstract][Full Text] [Related]
11. Modulation of B-cell abnormalities in lupus-prone (NZB x NZW)F1 mice by normal bone marrow-derived B-lineage cells.
Shao DZ; Yamada S; Hirayama F; Hirano H; Ono S; Hamaoka T
Immunology; 1995 May; 85(1):16-25. PubMed ID: 7635516
[TBL] [Abstract][Full Text] [Related]
12. Decrease in glomerulonephritis and Th1-associated autoantibody production after progesterone treatment in NZB/NZW mice.
Hughes GC; Martin D; Zhang K; Hudkins KL; Alpers CE; Clark EA; Elkon KB
Arthritis Rheum; 2009 Jun; 60(6):1775-84. PubMed ID: 19479860
[TBL] [Abstract][Full Text] [Related]
13. Estrogen distinctively modulates spleen DC from (NZB x NZW) F1 female mice in various disease development stages.
Jiang B; Sun L; Hao S; Li X; Hou Y
Cell Immunol; 2007 Aug; 248(2):95-102. PubMed ID: 18061155
[TBL] [Abstract][Full Text] [Related]
14. Sophorae radix reduces autoimmune response in NZB/w F1 systemic lupus erythematosus mouse model.
Ko E; Lee Y; Park N; Cho C; Yim YN; Kim J; Kim YS; Kim D; Shin MK; Hong MC; Bae H
Lupus; 2007; 16(5):335-41. PubMed ID: 17576735
[TBL] [Abstract][Full Text] [Related]
15. Male New Zealand Black/KN mice: a novel model for autoimmune-induced permanent alopecia?
Hiroi A; Ito T; Seo N; Uede K; Yoshimasu T; Ito M; Nakamura K; Ito N; Paus R; Furukawa F
Br J Dermatol; 2006 Aug; 155(2):437-45. PubMed ID: 16882186
[TBL] [Abstract][Full Text] [Related]
16. Gr-1(high) CD11b+ cells suppress B cell differentiation and lupus-like disease in lupus-prone male mice.
Trigunaite A; Khan A; Der E; Song A; Varikuti S; Jørgensen TN
Arthritis Rheum; 2013 Sep; 65(9):2392-402. PubMed ID: 23754362
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulatory effects of H.P. Acthar Gel on B cell development in the NZB/W F1 mouse model of systemic lupus erythematosus.
Decker DA; Grant C; Oh L; Becker PM; Young D; Jordan S
Lupus; 2014 Jul; 23(8):802-12. PubMed ID: 24759631
[TBL] [Abstract][Full Text] [Related]
18. Prolactin and systemic lupus erythematosus.
McMurray RW
Ann Med Interne (Paris); 1996; 147(4):253-8. PubMed ID: 8952744
[TBL] [Abstract][Full Text] [Related]
19. Acceleration of lupus erythematosus-like processes by low frequency noise in the hybrid NZB/W mouse model.
Aguas AP; Esaguy N; Grande NR; Castro AP; Castelo Branco NA
Aviat Space Environ Med; 1999 Mar; 70(3 Pt 2):A132-6. PubMed ID: 10189170
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-21 receptor blockade inhibits secondary humoral responses and halts the progression of preestablished disease in the (NZB × NZW)F1 systemic lupus erythematosus model.
Zhang M; Yu G; Chan B; Pearson JT; Rathanaswami P; Delaney J; Ching Lim A; Babcook J; Hsu H; Gavin MA
Arthritis Rheumatol; 2015 Oct; 67(10):2723-31. PubMed ID: 26097207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
